Published in Arthritis Res Ther on February 27, 2013
Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci (2013) 3.94
Interleukin-2 treatment reverses effects of cAMP-responsive element modulator α-over-expressing T cells in autoimmune-prone mice. Clin Exp Immunol (2015) 0.88
IL-33 neutralization suppresses lupus disease in lupus-prone mice. Inflammation (2014) 0.81
[Regulatory T‑cells in systemic lupus erythematosus : IL-2 is decisive for loss of tolerance]. Z Rheumatol (2016) 0.80
Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS One (2015) 0.79
Foxp3, Regulatory T Cell, and Autoimmune Diseases. Inflammation (2016) 0.75
Regulatory T cell-deficient scurfy mice develop systemic autoimmune features resembling lupus-like disease. Arthritis Res Ther (2015) 0.75
Granulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells. BMC Nephrol (2016) 0.75
[Regulatory T cells and rheumatic diseases]. Z Rheumatol (2015) 0.75
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol (2006) 14.33
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48
Murine models of systemic lupus erythematosus. Adv Immunol (1985) 9.79
Systemic lupus erythematosus. N Engl J Med (2011) 7.79
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2009) 4.90
Systemic lupus erythematosus. Cell (1996) 4.21
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 3.22
From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol (2001) 3.02
Pathogenesis of systemic lupus erythematosus. J Clin Pathol (2003) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med (2010) 2.35
Clinical pharmacology of cyclophosphamide. Cancer Res (1973) 2.08
Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol (2005) 2.00
Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum (1991) 1.98
Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol (2004) 1.92
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol (2011) 1.82
Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol (2005) 1.76
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol (2009) 1.71
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
Human regulatory T cells and autoimmunity. Eur J Immunol (2008) 1.54
Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol (2009) 1.41
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother (2010) 1.38
Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.33
Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res (2010) 1.32
Adaptation of humoral memory. Immunol Rev (2006) 1.29
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol (2008) 1.19
CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum (2009) 1.18
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Key autoantigens in SLE. Rheumatology (Oxford) (2005) 0.95
Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci (2012) 0.93
CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol (2010) 0.91
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol (2012) 0.89
Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum (1979) 0.86
The NIH pulse cyclophosphamide regime: the end of an era? Lupus (2004) 0.84
Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol (2004) 0.83
A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. Int J Cancer (2011) 0.79
[Regulatory T cells in rheumatic diseases]. Dtsch Med Wochenschr (2006) 0.79
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum (2010) 2.27
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med (2014) 2.16
Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.81
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol (2012) 1.46
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther (2012) 1.44
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 1.41
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38
In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol (2007) 1.25
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension (2011) 1.24
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis (2012) 1.21
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis (2009) 1.13
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis (2007) 1.08
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) (2012) 1.06
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis (2010) 1.05
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther (2009) 1.01
IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis (2012) 0.99
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis (2012) 0.98
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther (2009) 0.98
Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum (2002) 0.95
Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur J Immunol (2010) 0.94
Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 0.94
The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One (2013) 0.91
Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European Study (EUSTAR). J Rheumatol (2010) 0.90
CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice. Arthritis Rheum (2011) 0.90
Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol (2008) 0.89
Two-dimensional speckle tracking of the left ventricle in patients with systemic sclerosis for an early detection of myocardial involvement. Eur Heart J Cardiovasc Imaging (2012) 0.89
Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol (2012) 0.88
Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.88
Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxford) (2011) 0.88
Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis (2013) 0.86
Apoptotic marginal zone deletion of anti-Sm/ribonucleoprotein B cells. Proc Natl Acad Sci U S A (2012) 0.85
Simultaneous cytometric analysis of (auto)antigen-reactive T and B cell proliferation. Immunobiology (2002) 0.85
Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Ann Rheum Dis (2011) 0.85
Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol (2011) 0.85
Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmun Rev (2011) 0.84
Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther (2009) 0.84
Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.83
Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol (2004) 0.83
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis (2012) 0.83
Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther (2010) 0.83
Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovasc Ultrasound (2010) 0.83
Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Res Ther (2012) 0.83
Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum (2009) 0.82
A cold-response index for the assessment of Raynaud's phenomenon. J Dermatol Sci (2006) 0.82
Functional autoantibodies in systemic sclerosis pathogenesis. Curr Rheumatol Rep (2015) 0.81
Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther (2014) 0.81
Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis (2010) 0.81
New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis (2013) 0.81
Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol (2010) 0.81
Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.81
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther (2014) 0.80
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis (2011) 0.80
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol (2015) 0.80
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J (2014) 0.79
Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. Rheumatol Int (2008) 0.79
Osteopontin in the development of systemic sclerosis--relation to disease activity and organ manifestation. Rheumatology (Oxford) (2010) 0.79
Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle. Cardiovasc Ultrasound (2014) 0.78
The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: results from a multicenter study of European Caucasian patients. Hum Immunol (2008) 0.78
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol (2011) 0.78
Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol (2014) 0.78
Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response. Autoimmun Rev (2016) 0.77
Infrared-mediated hyperthermia is effective in the treatment of scleroderma-associated Raynaud's phenomenon. J Invest Dermatol (2005) 0.77
The functional polymorphism 844 A>G in FcαRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility. J Rheumatol (2010) 0.76
Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain. J Clin Immunol (2006) 0.76
Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol (2011) 0.76
Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int (2011) 0.76
Functional autoantibodies in systemic sclerosis. Semin Immunopathol (2015) 0.76
Reply: vascular receptor autoantibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med (2015) 0.75
[Regulatory T cells - a possible promising target in the treatment of autoimmune diseases]. Z Rheumatol (2003) 0.75
[Systemic sclerosis]. Dtsch Med Wochenschr (2016) 0.75
[Granulomatosis with polyangiitis]. Dtsch Med Wochenschr (2017) 0.75
An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. J Rheumatol (2017) 0.75
Influence of bosentan on fingertip rewarming in patients with systemic sclerosis. J Dtsch Dermatol Ges (2013) 0.75